Given that the therapeutic effect of anti-PD-1 antibodies depends on the frequency of tumor-infiltrating CD8 T cells (8), combining anti-PD-1 antibodies with the immunostimulatory agents that induce tumor-specific CD8 T cells may be a sensible strategy for improving anti-PD-1 antibody therapeutic effect. This evidence concerns the gene CD8A and neoplasm.